This is a list of global response funds and funding opportunities related to COVID-19 relief. This list was complied using publicly available information and while we strive to be comprehensive, we may have missed your fund. If you would like your fund to be included, please fill out the submission form at www.cof.org/covid19fund
USAID/GH is seeking Concept Papers that incorporate interventions that will build upon and expand USAID’s efforts to better connect communities and health systems, as part of the COVID-19 response as well as in strengthening and adapting existing health systems to their communities for COVID-19 preparedness and response. In particular, awards will support national, subnational, regional, and local policies and implementation plans to prioritize COVID-19 interventions along with continuity of existing primary health care, local needs, and priorities for response, recovery and resilience, including the oxygen ecosystem, defined as the constellation of commodities, training, equipment and support needed for the production and distribution of oxygen, and its safe, appropriate and effective use.
Questions related to the Addendum are due by August 14, 2020 at 12:00 pm EDT. The first round of Concept Papers are due by August 24, 2020 at 12:00 pm EDT.
If you are interested in this opportunity, please contact Eric Bergthold, Executive Director, Office of Global Projects.
The Computing Research Association (CRA) and the Computing Community Consortium (CCC) are pleased to announce a new Computing Innovation Fellows (CIFellows) Program for 2020. This program recognizes the significant disruption to the academic job search caused by the COVID-19 pandemic and associated economic uncertainty. Its targets include recent and soon-to-be PhD graduates in computing whose academic job search was impacted by COVID-19 and aims to provide them with a career-enhancing bridge experience.
The goal of this program is to create career growth opportunities that support maintaining the computing research pipeline. Computing research is defined as any area included under the National Science Foundation (NSF) Computing and Information Science and Engineering (CISE) Directorate. This effort takes inspiration from CRA/CCC’s NSF-funded Computing Innovation Fellows Programs with cohorts starting 2009, 2010, and 2011 and CRA’s Best Practices Memo on Computer Science Postdocs.
NIGMS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need of documenting COVID-19-related patient outcomes among medically underserved populations.
Background
Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals. There are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus, SARS-CoV-2, was identified as the causative agent of an outbreak of viral pneumonia centered around Wuhan, Hubei Province, China. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Fatality rates of COVID-19 patients among racial and ethical minorities, and residents of rural areas and underserved urban communities appear to be significantly higher than that of other populations. Documentation of COVID-19-related outcomes of patients from medically underserved populations is crucial to understanding the impact and to effectively combating the pandemic. The IDeA-Clinical Translational Research (IDeA-CTR) networks are uniquely positioned to address this need; they are located in IDeA states that typically have less access to medical research resources and are focused on addressing health challenges of medically underserved populations .
This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts,including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.
Background
As people across the United States and the rest of the world respond to the COVID-19 pandemic, the importance of behavioral and social factors in health and illness is being highlighted. Most of the current mitigation efforts are non-pharmacological interventions grounded in social and behavioral principles of prevention (e.g. risk communication, handwashing adherence, physical distancing, working from home, paid sick leave). The evidence base for many of these containment and mitigation efforts is based on limited research from prior influenza and SARS epidemics. However, we have minimal experience with a pandemic of this scope and the impacts of these extensive containment and mitigation efforts on transmission rates. Moreover, we have limited understanding of the impact on the personal and economic costs and downstream health and well-being impacts such as suicide and mental health exacerbations, substance abuse, adoption or reduction in healthy lifestyle behaviors (e.g tobacco use, dietary and physical activity regimens), and stress-based physical disorders.
The impact of the COVID-19 pandemic on the nation is vast, especially on health and well-being. Research suggests that alcohol consumption tends to increase during times of duress and uncertainty such as disasters and other traumatic events, and as such alcohol is often misused to cope with stress, anxiety, and other uncomfortable emotions. In addition, the misuse of alcohol to cope with the stress as a result of physical distancing and other policy measures, and a lack of access to supportive social networks and treatment for people with pre-existing alcohol use disorder (AUD) are significant concerns during the pandemic. These outcomes are particularly challenging with respect to COVID-19 because alcohol misuse can interfere with normal immune system function and elevate susceptibility to viral infections of the respiratory system. Alcohol-associated damage to the liver, heart, and other organs may also complicate health outcomes in individuals with COVID-19. These myriad physical and behavioral health outcomes related to alcohol and COVID-19 present a range of urgent research needs and opportunities.
Research is needed to understand the potentially complex relationships between alcohol consumption and COVID-19 related-outcomes to enhance the nation’s response to the current pandemic. The outcomes include overt pathophysiology and the impact of social and policy measures on COVID-19 outcomes. Such studies also will help to lay the groundwork for responding to future public health emergencies. This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.
NIAAA is encouraging research in the following areas, including those that capitalize on existing research cohorts, to investigate urgent research questions of significance to the COVID-19 pandemic within the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).
Background
Translating biomedical discoveries into clinical applications is essential to improving human health. It is also a complex process with high costs and substantial failure rates. These failures can result in delays of years or decades before improved patient outcomes result from discoveries in biomedical research. Under NCATS’ leadership, the CTSA Program supports a national consortium of medical research institutions that work together to tackle system-wide scientific and operational changes that solve the many outstanding problems limiting the efficiency, effectiveness, and reach of clinical translational research, and thus get more treatments to more patients more quickly across the country. To do that, the program focuses on widely appreciated systematic barriers.
Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus, COVID-19, was identified as the causative agent of an outbreak of viral pneumonia centered around Wuhan, China. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website (https://www.cdc.gov/coronavirus/index.html) and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of the disease are poorly understood. Given this, there is an urgent public health need to better understand the COVID-19.
Purpose
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.
NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.
Many existing experimental drugs, FDA approved drugs, and biologics already have been tested in humans, and detailed information is available about their pharmacology, formulation, and potential toxicity. By building upon previous research and development efforts, new uses for existing drugs or biologics can be advanced to testing in clinical trials more quickly than starting from scratch. If a new therapy receives regulatory approval, it can be efficiently integrated into clinical practice. Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus therapeutics. In January 2020, a novel coronavirus, SARS-CoV-2, was identified as the causative agent of an outbreak of viral pneumonia. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of the disease are poorly understood. Given this, there is an urgent public health need to better understand COVID-19 and find therapies to treat infections.